Clinical trial
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic…
NCT00005639 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00005639 |
|---|---|
| Title | Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment |
| Official title | A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | Azacitidine Injection, sodium phenylbutyrate |
| Enrollment | 34 |
| Start date | Mar 1, 2000 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: